Abstract
INTRODUCTION
Hypercholesterolemia is characterized by increase in serum cholesterol level above the normal values (> 200 mg/dL). It is often associated with the elevated of serum lowdensity lipoprotein cholesterol (LDL-C) concentration because it carried 65-75 % of total cholesterol (TC) [1, 2] .
The incidence of hypercholesterolemia will continue to grow unanimously as the unhealthy lifestyle such as smoking, obesity, lack of exercise and the consumption of high-fat meals. The increase of TC and LDL-C can be modified by nonpharmacology therapy, such as changes in life style and habits (e.g., inclulging in exercise, diet and no smoking) and pharmacotherapy (medication use) [3] ; thus, the process of atherosclerosis can be prevented as early as possible [4] [5] [6] [7] .
Morinda citrifolia (MC) is commonly known as "Noni" [8, 9] . MC fruit has been used as a traditional medicine for about 2000 years. It has many effects and activities, such as antibacterial, antiviral, anti-diabetes, antihypertensive, immunostimulatory, and anticancer [10] . MC fruit contains polysaccharides, fatty acid, glycosides, iridoids, anthraquinones, coumarins, flavonoids, lignans, phytosterols, and carotenoids [9] . MC has a wide safety range, its LD 50 more than 15.000 mg/kg [11, 12] and can be tolerated up to 10 g/day with no side effects [13] . MC is one of many plants with fruit that could decrease the TC and LDL-C and has been studied in mice [14] . Series of clinical studies in America proved that MC fruit juice could decrease the TC and LDL-C significantly in hypercholesterolemia patients with smoking habits [15] [16] [17] . The clinical usage of MC fruit in hypercholesterolemia patients as reported warrants further evaluation in more subjects. In this study, we evaluated the effect of oral administration of MCC in 60 subjects with hypercholesterolemia.
EXPERIMENTAL Materials
Each 500 mg Morinda citrifolia capsule (MCC) containing 90 % dry extract of MC fruits and 10 % filler and was registered for sale in Indonesia.
Design
This study was conducted between April and October 2012, and was a double-blind design, randomized controlled clinical trial, conducted in patients at a clinic in South Jakarta, Indonesia.
METHODS
Subjects were randomly assigned into two groups: MCC group and the P group. Each subjects received a material study and they were monitored every Monday and Thursday to evaluate the outcome for 14 days. The age, sex, body mass index, and compliance of all the subjects with the standard diet regimen (low fat diet), exercise, and smoking behavior was assessed using a questionnaire, based on crosssectional study, at the end of study. Blood samples were collected twice a week to determine the TC and LDL-C values in the laboratory during the study. The values of TC and LDL-C were determined from fasting blood cholesterol. They were measured at baseline, day 3, 7, 10 and 14 of study period. Overnight fasting venous blood (3 mL) was taken from each subject each time the measurements were done. The TC and LDL-C were measured using enzymatic methods by spectrophotometric assays on automated chemistry analyzer. The blood was taken at the laboratory of Biomedika, South Jakarta, Indonesia and analyzed using a reagent kit (Roche Diagnostics, GmBH, Manheim, Germany)
Subjects
The Ethics Committee of the Faculty of Medicine, University of Indonesia -Cipto Mangunkusumo Hospital, Central Jakarta, Indonesia reviewed the research protocol used and approved it (Reg. no. 127/PT02.FK/ETIK/2012); followed the guidelines of World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects [18] . The 60 subjects were selected for the study using the following criteria. The inclusion criteria for this study are diagnosis of hypercholesterolemia with an increased TC > 200 mg/dL and LDL-C > 130 mg/dL, in males and females, aged over 30 years and willing to give informed consent. Exclusion criteria were the use of supplement or drugs that will interfere with cholesterol metabolism, pregnant and breast feeding women, women with hormone replacement therapy, and patients with chronic disease. Reasons for dropping out of the study include non-compliance to protocol agreed upon at the beginning of the study, change in the type of drug that has been established at the beginning of the study, patient experiencing side effects of MCC and refusal to continue the research.
Statistical analysis
The data was analyzed by descriptive and analytical method using Students' t-and Chi square tests. Significance level was set at p < 0.05 and all data were analyzed using a statistical software package (SPSS, version 17.0).
RESULTS

Characteristics of subjects
The results showed that patients who had serum total cholesterol > 200 mg/dL and LDL cholesterol > 130 mg/dL were mainly those whose age were < 40 years old (53.3 %). Overweight patients (BMI > 25 kg/m 2 ) were 55 %. Also, 28.3 % of patients do not engage in regular exercise. Patients on low fat diet constituted 60 % while others were not. Most of the patients were non-smokers (73.3 %).
Effect of MCC in hypercholesterolemic patients
This study also showed a significant reduction of total and LDL cholesterol in experimental group compared to control group (Figures 1 and 2 ). As Table 2 shows, there were differences in TC and LDL-C levels in the two groups (p < 0.05).
There was no significant difference in TC and LDL-C levels from baseline level to day 14 in the control group but there was a significant decrease in TC and LDL-C levels in the experimental group at day 14. The reductions in TC and LDL-C were 13.8 % (33.0 mg/dL) and 15.5 % (26.6 mg/dL), respectively, using control group as the baseline. But, MCC could not increase HDL-C or decrease TG because the result showed that there are no significant differences (p > 0.05).
Bivariate analysis
The correlation between TC and factors that could influence the concentration of TC, such as age, sex, BMI, exercise, diet and smoking habits at the experimental group were analyzed but that between LDL-C level and the factors was not because LDL-C is the major component of TC [1] . When TC increases, the LDL-C will automatically increase too. Therefore, it would be more accurate to analyze correlation between TC and all of factors. From this study, sex did not give a significant decrease in TC level. Theoretically, before the age of 50, TC in males might be higher than in females at the same age. But, after the age of 50 the reverse is the case. It is caused by hormonal effect in females after menopause. After menopause (natural or surgical) TC would rise so LDL-C rises too [5] . However, there were some studies which showed that sex did not affect the TC reduction. John et al [25] in his research stated that control of dyslipidemia did not vary significantly across ethnic-sex group and prevalence of dyslipidemia did not differ significantly between women and men. Cooke and Hammerash [26] also reported the same. They showed that there were no significant sex differences in potency groups to manage dyslipidemia. Another study by Syed et al [27] showed that there were no significant reductions in serum TC and LDC-C levels in both male and female patients (p > 0.05).
Another factor was BMI. In this study BMI gave OR = 6.2 and p = 0.0001. This result shows that there was a significant correlation between BMI and TC reduction. Freeman and Junge [5] stated that high BMI or body weight increases the risk of a higher TC level. Denke [28] explained that there was a relationship between body weight changes and serum TC level among people between adults and middle age.
Exercising regularly could lower the levels of TC, LDL-C, and triglycerides in humans [29] . This study shows a significant difference between patients who exercised regularly and those who did not (OR = 14; p = 0.001). Kuriyan et al [30] produced same results with this study. They explained that physical activity reduces most of the artherosclerotic risk factors and regular exercise has been shown to reduce LDL-C and triglycerides.
Lifestyle modification to normalize body weight and having healthy patterns of dietary intake might give a significant result in serum TC reduction. Individualized dietary intake for reducing TC level in blood have shown to be modestly effective. Diets low in saturated fat and cholesterol could lower LDL-C [30]. Our study showed that diet could decrease TC level. A comparison between patients with a good diet and those without showed significant differences in TC reduction (OR = 16.3; p = 0.0001).
One other factor that influenced the reduction of TC level was smoking habits (OR = 14; p = 0.001). A cigarette contains many toxins such as tar, nicotine and carbon monoxide. Smoking can decrease the oxygen serum level and lead to elevation in heart rate, reduction in high density lipids (HDL) and damage of endothelium [31] . Jacobson [32] stated that there was a correlation between smoking and TC level while Schultemaker [33] explained that there was a significant difference in the TC levels of patients who smoked and those who do not. Shi-Dou Lin et al [34] also found that TC level is related to smoking habits. Thus, the findings are buttressed those of the cited above, especially with regard to correlation between smoking habit and reduction in TC level.
No serious adverse effects were reported during the present study. Adverse events were just limited to mild gastrointestinal symptoms such as flatulence and abdominal distention after the first few doses but the symptoms subsided within a week in all subjects.
CONCLUSION
The results indicate that 1 g extract, when given orally three times a day, significantly reduces TC and LDL-C levels. It seems that consumption of MCC when combined with suitable control of some factors such as age, BMI, diet, exercise and smoking habit significantly reduces TC levels in patients. The results from this study justify the medicinal use of Morinda citrifolia in hypercholesterolemia and may also be of relevance in the treatment of cardiovascular diseases. 
